Medivation Inc. and Astellas Up the Ante against Johnson & Johnson

Positive late stage results pave the way for Medivation and Astellas to expand Xtandi's label, putting it even more directly in competition with Johnson's Zytiga.

Jan 29, 2014 at 11:01AM

Thanks to data announced in October, investors already knew Medivation (NASDAQ:MDVN) and Astellas Pharma's phase 3 trial showed their prostate cancer drug Xtandi was impressive in treating patients who hadn't yet received chemotherapy.

Now, with fresh data in hand, we can see just how compelling the argument is for the FDA to approve the company's bid to expand Xtandi's label to include that all important pre-chemotherapy indication. If the FDA does agree to expand Xtandi's use, it could erase a competitive advantage currently held by Johnson & Johnson's (NYSE:JNJ) blockbuster prostate cancer treatment Zytiga.

Label expansion
The chance to market Xtandi to the pre-chemo patient pool could mean a significant bump up in revenue for both Medivation and its partner Astellas. Xtandi is currently Medivation's only marketed drug; after Johnson & Johnson's Zytiga got the nod for pre-chemotherapy use in December 2012, it kicked off a surge in sales that helped Zytiga's revenue jump more than 60% to $750 million in the U.S. during 2013.

Despite Xtandi being compared to placebo during phase 3 while Zytiga was compared to prednisone, a steroid commonly prescribed as part of prostate cancer therapy, results suggest Xtandi put up results as good as, and possibly even better than, Zytiga in this patient pool. Following the release of additional trial data this month, it's hard to believe the FDA won't eventually grant Xtandi the go-ahead. Especially, when considered in the context of the data behind the FDA approving Zytiga for the indication.

Patients taking Xtandi not only saw overall survival improve, but were also able to delay chemotherapy treatment by 17 months versus placebo. In pre-chemotherapy phase 3 trials for Zytiga, patients were able to delay chemotherapy by 8.4 months versus prednisone.

Xtandi patients, who had all previously failed on androgen deprivation therapy, saw their risk of death drop 29% versus placebo and their risk of radiographic progression, or rPFS, or death fall 81% when compared to the placebo group. In Zytiga's trial, the risk of death dropped 25% and the rPFS fell 57% versus prednisone.

Looking at it another way, those patients taking Xtandi reported a delay in deterioration in quality of life of 11.3 months, versus 5.6 months for placebo, a 5.7 month improvement. Patients taking Zytiga saw the time to deterioration improve to 12.7 months from 8.3 months for those taking only prednisone, a 4.4 month improvement.

Fool-worthy final thoughts
Metastatic castration-resistant prostate cancer causes 258,000 deaths worldwide each year, so the need for new, more effective treatment remains.

Since each was compared against a different control during clinical trials, it's tough to make an apples-to-apples comparison of Xtandi and Zytiga. However, compelling results for Xtandi means it's likely we'll see an sNDA filed for the indication soon and an eventual FDA approval. If so, Xtandi will likely cut into sales that otherwise would've headed to Zytiga. A dynamic that may already be playing out in off-label use given Zytiga's U.S. sales have been slowing sequentially while Xtandi's have been growing.

1 stock pick to know in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Todd Campbell owns Medivation.  Todd owns E.B. Capital Markets, LLC.  E.B. Capital's clients may or may not have positions in the companies mentioned.  Todd also owns Gundalow Advisors, LLC.  Gundalow's clients do not have positions in the companies mentioned.The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers